GlaxoSmithKline begins clinical development of H1N1 vaccine

GlaxoSmithKline has revealed that its clinical programme for the development of a H1N1 virus vaccine has begun.

Enrolment for the study has also been completed, the group confirmed at the close of last week. The first trials will be conducted in Germany and aim to examine the use of the vaccine in healthy adults, with the first results due to be submitted to regulatory bodies in September.

Chief executive and head of global clinical research and development for GlaxoSmithKline Dr Thomas Breuer said: “Enrolment into the first study has been completed and in total, GlaxoSmithKline will conduct 16 clinical trials of its pandemic vaccine in over 9000 individuals across Europe, Canada and the US.”

Among the aspects to be investigated are the immune response, safety and tolerability of the treatment in humans.

In associated news, GlaxoSmithKline’s joint venture with Shionogi announced that a clinical study for S/GSK1349572 is to take place jointly with the European AIDS Treatment Group and the AIDS Treatment Activists Coalition.